Green leaves
Trelegy: Now a carbon neutral triple therapy inhaler, as certified by the Carbon Trust.1

One part of delivering GSK’s commitment to have a net zero impact on climate and net positive impact on nature by 2030.

As a science-based healthcare company, addressing our environmental impact is fundamental to our purpose, so that together with our partners, we can help protect and restore the planet’s health.

What is carbon neutrality?

Hydrofluorocarbons contained in pressurised metered dose inhalers (pMDIs) are potent greenhouse gases and have a high Global Warming Potential (GWP). Dry powder inhalers (DPIs) don’t contain hydrofluorocarbons, however it doesn’t mean they don’t have an impact – almost everything we do as humans has an impact.

We have, and continue, to innovate in our manufacturing and distribution of Trelegy Ellipta to make it’s footprint on humanity as low as possible – but now we have taken one step further and offset the small carbon footprint it does have. This is what we mean by carbon neutral.

How have we achieved it?

To offset the small carbon footprint Trelegy Ellipta has, we are supporting a community re-forestation project based in Ghana – a project planting trees and improving sanitation and health.

This project restores forest reserves that have been degraded due to over exploitation, bush fires and conversion to agriculture.

In addition to delivering emissions removals to take climate action, this project aims to deliver a number of other benefits including:

  • providing work and opportunities for economic growth
  • Projects with a gender equality focus
  • Improving sanitation and access to clean water

Trelegy Ellipta prescribing information

TRELEGY Ellipta OD is indicated for maintenance treatment in adult patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an ICS and a LABA, or a combination of a LAMA and a LABA.3

References

  1. Certification of carbon neutrality for Trelegy Ellipta
  2. https://www.england.nhs.uk/greenernhs/a-net-zero-nhs/ (Accessed November 2021)
  3. Trelegy Ellipta SmPC

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.

© 2021 GSK Group of Companies or its licensor
Trademarks are the property of their respective owners
The Ellipta range was developed in collaboration with

Innoviva Logo

November 2021 | PM-GB-FVU-WCNT-210010 (V2.0)